Literature DB >> 20425522

Update on the assessment of children with juvenile idiopathic inflammatory myopathy.

Adam M Huber1.   

Abstract

The availability of validated measurement tools to assess children with juvenile idiopathic inflammatory myopathies is critical to clinical care and to ongoing research into new therapeutic modalities and approaches. Recent work has led to the development of tools for assessment of muscle strength and physical function, skin disease, global disease activity and damage, extramuscular disease, and quality of life. Ongoing work is attempting to integrate these assessments into core sets and definitions of improvement and flare. Future work will refine these assessments and definitions and--where there are multiple choices--determine which tools constitute an optimal assessment.

Entities:  

Mesh:

Year:  2010        PMID: 20425522     DOI: 10.1007/s11926-010-0103-4

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  47 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  Decreased levels of CD54 (ICAM-1)-positive lymphocytes in the peripheral blood in untreated patients with active juvenile dermatomyositis.

Authors:  M R O'Gorman; L Bianchi; D Zaas; V Corrochano; L M Pachman
Journal:  Clin Diagn Lab Immunol       Date:  2000-07

3.  Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group.

Authors:  D J Lovell; C B Lindsley; R M Rennebohm; S H Ballinger; S L Bowyer; E H Giannini; J E Hicks; J E Levinson; R Mier; L M Pachman; M H Passo; M D Perez; A M Reed; K N Schikler; M Smith; L S Zemel; L G Rider
Journal:  Arthritis Rheum       Date:  1999-10

Review 4.  Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies.

Authors:  F W Miller; L G Rider; Y L Chung; R Cooper; K Danko; V Farewell; I Lundberg; C Morrison; L Oakley; I Oakley; C Pilkington; J Vencovsky; K Vincent; D L Scott; D A Isenberg
Journal:  Rheumatology (Oxford)       Date:  2001-11       Impact factor: 7.580

5.  The Cutaneous Assessment Tool: development and reliability in juvenile idiopathic inflammatory myopathy.

Authors:  A M Huber; E M Dugan; P A Lachenbruch; B M Feldman; M D Perez; L S Zemel; C B Lindsley; R M Rennebohm; C A Wallace; M H Passo; A M Reed; S L Bowyer; S H Ballinger; F W Miller; L G Rider
Journal:  Rheumatology (Oxford)       Date:  2007-10       Impact factor: 7.580

6.  Neopterin and quinolinic acid are surrogate measures of disease activity in the juvenile idiopathic inflammatory myopathies.

Authors:  Lisa G Rider; Adam S Schiffenbauer; Mark Zito; Ken L Lim; Alaa Ahmed; Lawrence S Zemel; Robert M Rennebohm; Murray H Passo; Ronald M Summers; Jeanne E Hicks; Peter A Lachenbruch; Melvyn P Heyes; Frederick W Miller
Journal:  Clin Chem       Date:  2002-10       Impact factor: 8.327

7.  Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis.

Authors:  R Q Klein; C A Bangert; M Costner; M K Connolly; A Tanikawa; J Okawa; M Rose; S S Fakharzadeh; D Fiorentino; L A Lee; R D Sontheimer; L Taylor; A B Troxel; V P Werth
Journal:  Br J Dermatol       Date:  2008-07-04       Impact factor: 9.302

8.  Nuclear envelope dystrophies show a transcriptional fingerprint suggesting disruption of Rb-MyoD pathways in muscle regeneration.

Authors:  Marina Bakay; Zuyi Wang; Gisela Melcon; Louis Schiltz; Jianhua Xuan; Po Zhao; Vittorio Sartorelli; Jinwook Seo; Elena Pegoraro; Corrado Angelini; Ben Shneiderman; Diana Escolar; Yi-Wen Chen; Sara T Winokur; Lauren M Pachman; Chenguang Fan; Raul Mandler; Yoram Nevo; Erynn Gordon; Yitan Zhu; Yibin Dong; Yue Wang; Eric P Hoffman
Journal:  Brain       Date:  2006-02-14       Impact factor: 13.501

9.  Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis.

Authors:  Adam M Huber; Elizabeth M Dugan; Peter A Lachenbruch; Brian M Feldman; Maria D Perez; Lawrence S Zemel; Carol B Lindsley; Robert M Rennebohm; Carol A Wallace; Murray H Passo; Ann M Reed; Suzanne L Bowyer; Susan H Ballinger; Frederick W Miller; Lisa G Rider
Journal:  Arthritis Rheum       Date:  2008-02-15

Review 10.  MRI in juvenile idiopathic arthritis and juvenile dermatomyositis.

Authors:  Janet Mary McCrae Gardner-Medwin; Greg Irwin; Karl Johnson
Journal:  Ann N Y Acad Sci       Date:  2009-02       Impact factor: 5.691

View more
  3 in total

1.  Juvenile dermatomyositis: new insights and new treatment strategies.

Authors:  Neil Martin; Charles K Li; Lucy R Wedderburn
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-02       Impact factor: 5.346

Review 2.  Muscle involvement in systemic sclerosis: points to consider in clinical trials.

Authors:  Ulrich A Walker; Philip J Clements; Yannick Allanore; Oliver Distler; Chester V Oddis; Dinesh Khanna; Daniel E Furst
Journal:  Rheumatology (Oxford)       Date:  2017-09-01       Impact factor: 7.580

3.  Clinical characteristics and favorable long-term outcomes for patients with idiopathic inflammatory myopathies: a retrospective single center study in China.

Authors:  Xiao Ming Shu; Xin Lu; Yao Xie; Guo Chun Wang
Journal:  BMC Neurol       Date:  2011-11-09       Impact factor: 2.474

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.